目的：研究多西他赛（ DOC）联合表柔比星（ EPI）新辅助化疗方案治疗炎性乳腺癌（ inflammatory breast cancer，IBC）的临床疗效、毒性反应和预后。方法选择我院2008年7月-2013年10月收治的 IBC 53例，按化疗方案不同分为研究组22例和对照组31例，研究组应用 DOC 联合 EPI 治疗方案，对照组应用5-氟尿嘧啶（5-FU）联合EPI、环磷酰胺（ CTX）方案，21 d为1个周期，治疗4个周期后3~4周视情况行根治性切除术。术后评估两组临床疗效及毒性反应，随访1年，评价预后。结果研究组部分缓解率和总有效率均高于对照组（ P <0.05）。研究组1例、对照组2例因疾病进展未能接受手术治疗。随访1年，研究组远处转移率低于对照组，无瘤生存率高于对照组（P <0.05）。结论 DOC联合 EPI新辅助化疗方案治疗 IBC的临床疗效显著，毒副作用可耐受，可能是 IBC 新辅助化疗的优选方案。%Objective To observe the therapeutic efficacy,toxic reaction and prognosis of Docetaxel(DOC) combined with Epirubicin( EPI)on the neoadjuvant chemotherapy for inflammatory breast cancer( IBC). Methods A total of 53 IBC patients during July 2008 and October 2013 were divided into research group(n=22)and control group (n=31)based on different chemotherapies. The research group was treated with DOC combined with EPI,while the control group received 5-Fluorouracil(5-FU)combined with EPI and Cyclophosphamide(CTX),and one course was 21 d. Radical resection was performed 3-4weeks after a 4-course chemotherapy. Curative effect and toxic reaction were e-valuated after the operation in the two groups,and the prognosis was evaluated after one year of follow-up. Results Compared with those in control group,the values of partial remission and total effective rate were significantly higher in research group(P<0. 05). The radical resection was not performed because of developed pathogenetic condition for 1 patient in research group and 2 patients in control group. The one-year follow-up showed that the metastasis rate in re-search group was significantly lower than that in control group,while the disease free survival rate in research group was significantly higher than that in control group(P<0. 05). Conclusion Chemotherapy plan of Docetaxel combined with Epirubicin has better efficacy in the treatment of IBC,and the relevant toxic and side-effect are tolerable,thus it may be an preferred neoadjuvant chemotherapy plan for IBC.
展开▼
